Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 5.21 kCr |
| Price/Earnings (Trailing) | 124.2 |
| Price/Sales (Trailing) | 3.12 |
| EV/EBITDA | 28.2 |
| Price/Free Cashflow | 121.64 |
| MarketCap/EBT | 67.63 |
| Enterprise Value | 5.6 kCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | 6.9% |
| Price Change 1M | -3.1% |
| Price Change 6M | 19.2% |
| Price Change 1Y | 17.2% |
| 3Y Cumulative Return | 35% |
| 5Y Cumulative Return | -1.3% |
| 7Y Cumulative Return | 14.4% |
Cash Flow & Liquidity |
|---|
| Revenue (TTM) |
| 1.67 kCr |
| Rev. Growth (Yr) | 14.2% |
| Earnings (TTM) | 54.03 Cr |
| Earnings Growth (Yr) | 209.1% |
Profitability | |
|---|---|
| Operating Margin | 5% |
| EBT Margin | 5% |
| Return on Equity | 6.09% |
| Return on Assets | 3.13% |
| Free Cashflow Yield | 0.82% |
| Cash Flow from Investing (TTM) | -24.78 Cr |
| Cash Flow from Operations (TTM) | 83.36 Cr |
| Cash Flow from Financing (TTM) | -60.73 Cr |
| Cash & Equivalents | 70.77 Cr |
| Free Cash Flow (TTM) | 44.27 Cr |
| Free Cash Flow/Share (TTM) | 1.77 |
Balance Sheet | |
|---|---|
| Total Assets | 1.73 kCr |
| Total Liabilities | 839.61 Cr |
| Shareholder Equity | 886.52 Cr |
| Current Assets | 961.23 Cr |
| Current Liabilities | 504.37 Cr |
| Net PPE | 297.49 Cr |
| Inventory | 418.09 Cr |
| Goodwill | 274.65 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.26 |
| Debt/Equity | 0.51 |
| Interest Coverage | 0.33 |
| Interest/Cashflow Ops | 2.42 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend Yield | 0.27% |
| Shares Dilution (1Y) | 0.80% |
| Shares Dilution (3Y) | 0.90% |
Past Returns: Outperforming stock! In past three years, the stock has provided 35% return compared to 11.4% by NIFTY 50.
Technicals: Bullish SharesGuru indicator.
Balance Sheet: Strong Balance Sheet.
Size: Market Cap wise it is among the top 20% companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Smart Money: Smart money is losing interest in the stock.
Insider Trading: Significant insider selling noticed recently.
Past Returns: Outperforming stock! In past three years, the stock has provided 35% return compared to 11.4% by NIFTY 50.
Technicals: Bullish SharesGuru indicator.
Balance Sheet: Strong Balance Sheet.
Size: Market Cap wise it is among the top 20% companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Smart Money: Smart money is losing interest in the stock.
Insider Trading: Significant insider selling noticed recently.
Investor Care | |
|---|---|
| Dividend Yield | 0.27% |
| Shares Dilution (1Y) | 0.80% |
| Earnings/Share (TTM) | 1.67 |
Financial Health | |
|---|---|
| Current Ratio | 1.91 |
| Debt/Equity | 0.51 |
Technical Indicators | |
|---|---|
| RSI (14d) | 50.18 |
| RSI (5d) | 68.23 |
| RSI (21d) | 45.66 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal | Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
Summary of Sequent Scientific's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Management's outlook is optimistic following the recent merger approval between SeQuent and Viyash Group. The combined entity anticipates leveraging synergies to enhance growth, with a focus on sustainable profitability. Rajaram Narayanan stated that they aim for EBITDA margins in the high teens, having successfully achieved a 15.5% margin this quarter, with plans to reach a minimum of 20% in the upcoming fiscal year.
Key forward-looking points include:
Revenue Growth: In Q2 FY '26, revenues reached INR 4,240 million, marking a 15% year-on-year growth. Formulations, which represent 75% of sales, grew by 18%, indicating strong performance in major markets like Europe and emerging regions.
Expansion Plans: SeQuent is dedicated to diversifying its portfolio, particularly in the companion animal segment, where they see significant growth opportunities. The formulations business in India is projected to benefit from a newly expanded field force.
New Product Launches: The company plans to introduce several new products in the coming quarters, having launched 8 new products during the year in the U.S. They are strategically focusing on both therapeutic and nutritional products for companion animals.
Merger Benefits: With the merger in effect, management expects substantial synergy benefits that will optimize R&D and manufacturing processes, enhancing operational efficiencies. This is expected to yield significant cost improvements and product optimizations over 12 to 18 months.
Financial Improvements: The company reported a substantial profit after tax of INR 196 million, up from INR 63 million the previous year. Both SeQuent and Viyash are working towards reducing leverage and maximizing free cash flow.
Market Position: Management emphasized the robust demand in the animal health sector, driven by trends in food security and increased pet ownership, which provides a favorable backdrop for future growth.
The management remains committed to maintaining a strong balance sheet and achieving sustainable growth through strategic investments and operational enhancements.
Understand Sequent Scientific ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| CA HULL INVESTMENTS | 31.23% |
| CA HARBOR INVESTMENTS | 30.2% |
| QUANT MUTUAL FUND - QUANT SMALL CAP FUND | 5.5% |
| HARIBABU BODEPUDI | 2.77% |
| KALIDINDI SRIHARI RAJU | 2.49% |
| NARASIMHA REDDY DUTHALA | 1.28% |
Detailed comparison of Sequent Scientific against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| AVANTIFEED | Avanti Feeds | 10.29 kCr | 6.16 kCr | -8.10% | +10.80% | 16.63 | 1.67 | - | - |
| GODREJAGRO | Godrej Agrovet | 9.87 kCr |
Comprehensive comparison against sector averages
SEQUENT metrics compared to Pharmaceuticals
| Category | SEQUENT | Pharmaceuticals |
|---|---|---|
| PE | 124.20 | 33.48 |
| PS | 3.12 | 4.63 |
| Growth | 14.1 % | 8 % |
Sequent Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides animal health active pharmaceutical ingredients (APIs) formulations in the areas of anthelmintics, including endo and ecto parasiticides; and anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It also offers analytical solutions that support API, pharmaceutical, personal care, and nutraceutical organizations; and method validation, stability, and microbiology for APIs and finished products. The company was formerly known as PI Drugs & Pharmaceuticals Ltd. and changed its name to Sequent Scientific Limited in October 2009. The company was incorporated in 1985 and is headquartered in Mumbai, India. Sequent Scientific Limited is a subsidiary of CA Harbor Investments.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
SEQUENT vs Pharmaceuticals (2021 - 2026)
Here are the major questions and detailed responses from the Q&A section of the earnings transcript:
Question 1: "If you could guide, when can we see the merger close? So, can we -- so Q4, can we see the combined numbers?"
Answer: Yes, we can see the Q4 combined numbers. Once we receive the NCLT final order, we can start showing combined figures. However, we may even combine in Q3 itself.
Question 2: "And just some colour on your business, Viyash business, how much is API and how much is formulation?"
Answer: Our API and intermediates together account for around 65% to 70%, while the formulation represents about 30% to 35%. This can vary slightly quarter-on-quarter.
Question 3: "Are you seeing stronger growth in formulations versus API?"
Answer: Both segments are growing. The formulations business saw good growth due to new product launches and improved gross margins as we moved some production to India, which helps optimize costs.
Question 4: "How many launches have you done this year in the U.S.?"
Answer: We have executed around 8 product launches this year in the U.S. market, contributing positively to our growth trajectory.
Question 5: "SeQuent currently API R&D spending, I think around INR8 crores, INR10 crores. Can you confirm this?"
Answer: Yes, SeQuent's expenditure on API R&D stands at about INR8 crores to INR10 crores, reflecting our commitment to ongoing product validation and development.
Question 6: "Can you give guidance on sustainable margins for both entities going forward?"
Answer: We anticipate maintaining EBITDA margins of at least 20% and expect improvements, driven by continued operational efficiencies and product optimizations.
Question 7: "Regarding the impact of U.S. tariffs on business, what steps are you taking?"
Answer: Currently, our business is not significantly affected by tariffs. Only 35% of our business involves U.S. formulations, and our strong manufacturing network in the U.S. helps mitigate potential impacts.
Question 8: "What is your expected growth trajectory for Viyash?"
Answer: We aim for Viyash to grow at a CAGR of over 20% over the next three years, supported by new product launches and improved gross margins.
Question 9: "How do you plan to enhance margins despite rising costs?"
Answer: We focus on optimizing our product mix, controlling costs, and improving operational efficiencies to protect profits even as raw material prices fluctuate.
Question 10: "What will be your expected capex for FY '26 and '27?"
Answer: For FY '26 and the first half of FY '27, we don't anticipate significant capex. With potential inorganic opportunities, we may spend around INR100 crores to INR150 crores in FY '27, but it largely depends on finding suitable targets.
These summaries reflect the themes and specifics from the transcript as requested.
Distribution across major stakeholders
Distribution across major institutional holders
| 9.81 kCr |
| -9.30% |
| -28.80% |
| 22.66 |
| 1.01 |
| - |
| - |
| HESTERBIO | Hester Biosciences | 1.17 kCr | 313.12 Cr | -12.90% | -36.50% | 26.33 | 3.75 | - | - |
| VETO | VETO SWITCHGEARS AND CABLES | 188.47 Cr | 321.71 Cr | -15.10% | -24.90% | 9.2 | 0.59 | - | - |
| 419 |
| 387 |
| 388 |
| 361 |
| 381 |
| Profit Before exceptional items and Tax | 7.7% | 29 | 27 | 17 | 8.41 | 12 | 12 |
| Exceptional items before tax | -20% | -1.7 | -1.25 | -0.34 | -0.31 | -4.32 | 0 |
| Total profit before tax | 4% | 27 | 26 | 16 | 8.1 | 7.9 | 12 |
| Current tax | -52% | 7.24 | 14 | 13 | 8.83 | 7.98 | 11 |
| Deferred tax | 89.8% | 0.32 | -5.68 | -7 | -7.21 | -6.42 | -8.22 |
| Total tax | -5.6% | 7.56 | 7.95 | 5.93 | 1.62 | 1.56 | 2.94 |
| Total profit (loss) for period | 11.8% | 20 | 18 | 10 | 6.48 | 6.34 | 9.06 |
| Other comp. income net of taxes | -58.1% | 14 | 32 | 47 | -56.86 | 19 | -30.79 |
| Total Comprehensive Income | -31.2% | 34 | 49 | 57 | -50.38 | 26 | -21.73 |
| Earnings Per Share, Basic | 4.7% | 0.59 | 0.57 | 0.37 | 0.138 | 0.1 | 0.261 |
| Earnings Per Share, Diluted | 4.5% | 0.58 | 0.56 | 0.36 | 0.133 | 0.1 | 0.261 |
| 17.2% |
| 35 |
| 30 |
| 37 |
| 27 |
| 22 |
| 17 |
| Finance costs | -11.9% | 3.96 | 4.36 | 2.51 | 1.61 | 2.68 | 5.04 |
| Depreciation and Amortization | -3.4% | 8.67 | 8.94 | 9.12 | 9.59 | 9.13 | 8.95 |
| Other expenses | -14.3% | 49 | 57 | 76 | 84 | 99 | 75 |
| Total Expenses | -2.9% | 202 | 208 | 261 | 232 | 242 | 219 |
| Profit Before exceptional items and Tax | 417.9% | 27 | 6.02 | -9.75 | 16 | 43 | 23 |
| Exceptional items before tax | 18.9% | -4.88 | -6.25 | 0 | 0 | -2.56 | 0 |
| Total profit before tax | 1793.5% | 22 | -0.24 | -9.75 | 16 | 41 | 23 |
| Current tax | - | 3.88 | 0 | -0.57 | 0.37 | 6.08 | 3.18 |
| Deferred tax | 173.7% | 2.37 | -0.86 | -3.09 | 0.52 | 2.69 | -1.71 |
| Total tax | 382.3% | 6.25 | -0.86 | -3.67 | 0.89 | 8.77 | 1.47 |
| Total profit (loss) for period | 4047.4% | 16 | 0.62 | -6.08 | 15 | 32 | 21 |
| Other comp. income net of taxes | -18.6% | -0.15 | 0.03 | -12.05 | -35.32 | 90 | -48.58 |
| Total Comprehensive Income | 4385.7% | 16 | 0.65 | -18.13 | -20.52 | 123 | -27.24 |
| Earnings Per Share, Basic | 61.9% | 0.63 | 0.03 | -0.24 | 0.6 | 1.3 | 0.88 |
| Earnings Per Share, Diluted | 60.8% | 0.62 | 0.03 | -0.24 | 0.59 | 1.3 | 0.87 |
| -101.5% |
| 0.92 |
| 6.43 |
| 4.61 |
| 5.14 |
| 5.73 |
| 2.2 |
| Non-current investments | 0.9% | 653 | 647 | 642 | 640 | 637 | 632 |
| Loans, non-current | 8.9% | 430 | 395 | 378 | 369 | 353 | 323 |
| Total non-current financial assets | 3.9% | 1,086 | 1,045 | 1,023 | 1,012 | 993 | 958 |
| Total non-current assets | 3.1% | 1,149 | 1,115 | 1,094 | 1,082 | 1,069 | 1,038 |
| Total assets | 0.9% | 1,233 | 1,222 | 1,183 | 1,188 | 1,157 | 1,123 |
| Total non-current financial liabilities | -426.3% | 0 | 0.81 | 1.26 | 0 | 0.04 | 0.27 |
| Provisions, non-current | 4.4% | 2.43 | 2.37 | 2.14 | 2.21 | 2.01 | 2.54 |
| Total non-current liabilities | -37.5% | 2.87 | 3.99 | 5.78 | 2.21 | 2.05 | 2.8 |
| Borrowings, current | -48.8% | 23 | 44 | 35 | 46 | 32 | 19 |
| Total current financial liabilities | -40.3% | 44 | 73 | 66 | 87 | 85 | 58 |
| Provisions, current | -8.3% | 0.61 | 0.64 | 0.55 | 0.61 | 0.52 | 0.53 |
| Current tax liabilities | - | - | - | 2.81 | - | 0.61 | 0.61 |
| Total current liabilities | -36% | 49 | 76 | 69 | 98 | 92 | 62 |
| Total liabilities | -36.7% | 51 | 80 | 75 | 100 | 94 | 64 |
| Equity share capital | 0% | 50 | 50 | 50 | 50 | 50 | 50 |
| Total equity | 3.3% | 1,181 | 1,143 | 1,109 | 1,087 | 1,063 | 1,058 |
| Total equity and liabilities | 0.9% | 1,233 | 1,222 | 1,183 | 1,188 | 1,157 | 1,123 |
| 82% |
| -4.43 |
| -29.2 |
| 38 |
| 11 |
| - |
| - |
| Income taxes paid (refund) | -32.6% | -3.31 | -2.25 | 0.7 | 1.75 | - | - |
| Net Cashflows From Operating Activities | 92.4% | -1.12 | -26.94 | 38 | 9.36 | - | - |
| Proceeds from sales of PPE | -90.3% | 3.33 | 25 | 0 | 0.05 | - | - |
| Purchase of property, plant and equipment | 28.8% | 12 | 9.54 | 8.86 | 6.44 | - | - |
| Proceeds from sales of investment property | - | 0 | 0 | 23 | 0 | - | - |
| Cash receipts from repayment of advances and loans made to other parties | 43.6% | 8.15 | 5.98 | 0 | 0 | - | - |
| Dividends received | - | 0 | 0 | 0 | 4.12 | - | - |
| Interest received | 5.7% | 0.34 | 0.3 | 0.04 | 0.03 | - | - |
| Other inflows (outflows) of cash | - | -0.35 | 0 | 0 | 0 | - | - |
| Net Cashflows From Investing Activities | -132.2% | -0.44 | 5.47 | -50.7 | -4.25 | - | - |
| Proceeds from exercise of stock options | - | 7.47 | 0 | 0 | 11 | - | - |
| Proceeds from borrowings | -103.8% | 0 | 27 | 0 | 10 | - | - |
| Repayments of borrowings | - | 2.08 | 0 | -3.6 | 0 | - | - |
| Payments of lease liabilities | - | 0.96 | 0 | 0.98 | 0.78 | - | - |
| Dividends paid | - | 0 | 0 | 0 | 12 | - | - |
| Interest paid | -8.9% | 3.77 | 4.04 | 2.38 | 1.17 | - | - |
| Net Cashflows from Financing Activities | -101.6% | 0.66 | 22 | 0.24 | 7.24 | - | - |
| Net change in cash and cash eq. | -1087.5% | -0.9 | 0.84 | -12.71 | 12 | - | - |